Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs National Energy Services Reunited Corp Ordinary Shares (NESR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs National Energy Services Reunited Corp Ordinary Shares — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.13 (market cap $6.57B), while National Energy Services Reunited Corp Ordinary Shares trades at $19.5 (market cap $2.12B). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 3.1× National Energy Services Reunited Corp Ordinary Shares's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, National Energy Services Reunited Corp Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 1 Days and National Energy Services Reunited Corp Ordinary Shares for 0 Days on average.
| IOVA | NESR | |
|---|---|---|
Market Cap | $6.57B | $2.12B |
Volume | 11,838,721 | 3,257,316 |
Sector | Health | Energy |
52-Week High | $14.82 | $36.31 |
52-Week Low | $1.81 | $10.41 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $6.50B | $2.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iovance Biotherapeutics (IOVA) trades at $14.50, down 0.41% on the day, with a bullish technical signal from moving averages. The company shows strong revenue growth, with 2026 guidance raised to $410–420 million, but remains unprofitable with a net income margin of -89.09%. Recent news highlights institutional buying and positive analyst sentiment driven by accelerating adoption of its Amtagvi therapy.
The outlook is optimistic due to expanding TIL therapy applications and raised revenue guidance, but high cash burn and lack of profitability pose significant risks. Analyst consensus is strongly bullish with a $13.44 price target, though the stock faces volatility from clinical trial outcomes and competitive pressures.
NESR trades at $21.03, up 0.62% today, with neutral technical signals and strong fundamental momentum. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.44 exceeding expectations by 25%. Revenue growth remains robust, driven by Middle East operations including the Jafurah gas field expansion. Analyst sentiment is overwhelmingly positive with 83% buy ratings and a consensus price target of $41.80, representing nearly 100% upside potential.
The outlook remains favorable with projected revenue growth to $1.6B in 2026 and net profit doubling to $93M. Key risks include execution pressure from premium valuation and regional geopolitical uncertainties. The recent lithium extraction deal with Saudi Aramco provides additional growth optionality, though capital demands remain elevated. Current levels offer attractive entry for growth-oriented investors despite technical neutrality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About National Energy Services Reunited Corp Ordinary Shares
National Energy Services Reunited Corp (NESR) is a Houston-based oilfield services company that provides drilling, evaluation, and production services, including hydraulic fracturing, cementing, coiled tubing, and directional drilling, to oil and gas operators. It focuses primarily on markets across the Middle East, North Africa, and Asia Pacific.
Read more on NESR →
